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DOI 10.1016/j.ccr.2011.07.003SUMMARYConstitutional epimutations of tumor suppressor genesmanifest as promotermethylation and transcriptional
silencing of a single allele in normal somatic tissues, thereby predisposing to cancer. Constitutional MLH1
epimutations occur in individuals with young-onset cancer and demonstrate non-Mendelian inheritance
through their reversal in the germline. We report a cancer-affected family showing dominant transmission
of soma-wide highly mosaic MLH1 methylation and transcriptional repression linked to a particular genetic
haplotype. The epimutation was erased in spermatozoa but reinstated in the somatic cells of the next gener-
ation. The affected haplotype harbored two single nucleotide substitutions in tandem; c.-27C > A located
near the transcription initiation site and c.85G > T. The c.-27C > A variant significantly reduced transcriptional
activity in reporter assays and is the probable cause of this epimutation.INTRODUCTION
Altered DNA methylation is frequently observed in cancer cells
and includes both hypomethylation associated with activation
of oncogenes (Feinberg and Vogelstein, 1983), and hypermethy-
lation of the CpG island promoters of tumor suppressor genes
associated with transcriptional silencing (Greger et al., 1989;
Herman et al., 1998). More recently, constitutional epimutations
of DNA mismatch repair and tumor suppressor genes, including
MLH1, MSH2, DAPK1, and KILLIN, have been identified in
patients who do not carry a sequence mutation within the
cognate gene, yet have early-onset cancer consistent with
a familial cancer syndrome (Bennett et al., 2010; Chan et al.,
2006; Gazzoli et al., 2002; Raval et al., 2007). These so-calledSignificance
Constitutional epimutations of cancer-related genes represen
are caused by underlying cis-acting genetic alterations proxim
inheritance. However, the mechanistic basis forMLH1 epimuta
fined. This study of a cancer-affected family with dominant inh
ations provides evidence of a cis-genetic basis for constitution
germline c.-27C > A variant raises the interesting possibility t
within MLH1 and other genes may confer cancer susceptibil
This finding indicates a close interaction between genotype an
200 Cancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc.constitutional epimutations, characterized by monoallelic pro-
moter methylation and transcriptional silencing of the affected
allele within normal somatic tissues, represent another mecha-
nism for cancer predisposition.
Lynch syndrome is an autosomal dominant cancer suscepti-
bility syndrome characterized by the development of colorectal,
endometrial and other cancers demonstrating microsatellite
instability (MSI) as a consequence of defective mismatch repair,
usually at a young age (Lynch and Lynch, 2004). The syndrome is
typically caused by heterozygous germline mutations within the
coding region of the mismatch repair genes (Peltoma¨ki and
Vasen, 2004). A proportion of cases with suspected Lynch
syndrome, in whom no germline mismatch repair sequence
mutation is found, carry a constitutional epimutation of MLH1t an alternative mechanism for cancer predisposition. Some
ate to the affected gene and display autosomal dominant
tions that are reversible between generations remains unde-
eritance of a mosaicMLH1 epimutation through three gener-
al epigenetic silencing ofMLH1. The identification of a 50UTR
hat promoter variants of unknown pathogenic significance
ity through their association with epigenetic modifications.
d epigenotype in a cancer-associated gene.
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Suter et al., 2004) or MSH2 (Chan et al., 2006; Ligtenberg et al.,
2009). Individuals with an MSH2 epimutation exhibit tissue-
specificMSH2 promoter methylation, most apparent in epithelial
tissues. In these cases, somatic methylation is caused by a
cis-acting germline deletion encompassing the transcription
termination signal of the upstream EPCAM gene, which results
in elongation of transcription from EPCAM into MSH2 due to
failed transcription termination (Ligtenberg et al., 2009). Predict-
ably, families with MSH2 epimutations display autosomal domi-
nant inheritance. In contrast, constitutional MLH1 epimutations
are reported in individuals with a significant personal but not
familial history of cancer. Clear evidence of intergenerational
transmission of MLH1 epimutation has been reported in just
two families (Hitchins et al., 2007; Morak et al., 2008), one of
which showed non-Mendelian inheritance. In this family, the
affected mother transmitted her MLH1 epimutation to just one
of three sons, each of whom had inherited the identical maternal
allele, whereas the allele reverted to the normal functional state
in her other two sons (Hitchins et al., 2007). Moreover, MLH1
epimutations are erased in the spermatozoa of male carriers,
as evidenced by complete demethylation and transcriptional
reactivation of the somatically-affected allele (Hitchins and
Ward, 2007; Hitchins et al., 2007).
The mechanistic basis of constitutional MLH1 epimutation is
unknown. Certainly no primary genetic defect has been identi-
fied in the vicinity of the affected locus in carriers. Families with
constitutionalMLH1 and other epimutations offer an opportunity
to understand how epigenetic aberrations arise in humans.
Understanding the pattern of inheritance and etiology of consti-
tutional epimutations will inform genetic counseling and clinical
management. The goal of this studywas to investigate themech-
anistic basis of MLH1 epimutations and to define the pattern of
inheritance associated with them.
RESULTS
Haplotype-Specific Soma-Wide Mosaic MLH1
Epimutation in a Proband with Young-Onset
Colorectal Cancer
A previous population-based study of subjects from Western
Australia who had developed early-onset (<60 years) MSI colo-
rectal cancer identified 17 cases with a MLH1-deficient tumor
but no pathogenic germline mismatch repair mutation (Schofield
et al., 2009). To determine if these individuals carried a constitu-
tional MLH1 epimutation, we screened their peripheral blood
lymphocyte (PBL) DNA for the presence of MLH1 promoter
methylation by quantitative CpG methylation pyrosequencing
(Figure 1A). This led to the identification of one proband, aCauca-
sian female diagnosed with a right-sided colorectal cancer at
age 41 years, who had variable levels of MLH1 methylation
throughout her normal somatic tissues (Figure 1B). This was
confirmed by clonal bisulphite sequencing across the critical
region of the MLH1 promoter (see Figure S1 available online).
Sequencing of the entire CpG island encompassing the MLH1
promoter (2 kb upstream to 1 kb downstream of the first codon)
in the proband’s genomic DNA identified two heterozygous
single nucleotide substitutions within exon 1; c.-27C > A in the
50UTR and missense variant c.85G > T (rs63750656). The twogenetic alleles were separated by cloning, and resequencing
revealed a variant haplotype on which both the c.-27A and
c.85T variants were linked in tandem (Figure 1C). These two sites
were incorporated into assays designed to distinguish the epige-
netic modifications and transcriptional activity associated with
each genetic allele (Figure 2A). Allelic bisulphite sequencing
demonstrated that the methylation occurred specifically on the
variant haplotype and involved CpG sites flanking both nucleo-
tide substitutions (c.-27A and c.85T) (Figure 2B). Moreover,
bisulphite sequencing revealed a mixture of fully, partially and
unmethylated forms of the variant haplotype, indicative of
epigenetic mosaicism (Figure 2B). Chromatin immunoprecipita-
tion followed by allele-specific real-time PCR (ChIP-AS) in
cultured lymphoblastoid cells (LCLs) from the proband showed
a coalescence of repressive histone modifications including
H3-K9 and H3-K27 trimethylation, and depletion of the H3-K9
acetylation and H3-K4 trimethylation motifs permissive to tran-
scription, on the variant haplotype (Figure 2C). Quantitative
allelic expression analyses showed transcriptional repression
of the variant haplotype in different tissues, ranging from
complete to partial loss of expression, consistent with mosaic
epigenetic silencing (Figure 2D). This variable allelic expression
imbalance was confirmed at the benign c.655A > G SNP within
MLH1 exon 8, at which the proband was also informative (Fig-
ure S2A). An acquired loss-of-heterozygosity (LOH) of the wild-
type allele was detected in the tumor by allele quantification,
accounting for its loss of MLH1 and MSI (Figure 2E; Figure S2B).
In summary, the proband bore a mosaic soma-wide MLH1 epi-
mutation with variable transcriptional suppression on a variant
genetic haplotype, marked by c.-27C > A and c.85G > T substi-
tutions, as the probable cause of her cancer susceptibility.
Dominant Intergenerational Transmission of the MLH1
Epimutation Linked to the Variant Haplotype
The proband reported a family history of Lynch syndrome-asso-
ciated cancers. Specifically her brother had a colorectal cancer
at 46 years of age that also failed to express MLH1 and was
MSI, while her mother developed endometrial and metachro-
nous colorectal cancers at a young age. Twelve members
from three generations of the family, designated family 16, con-
sented to join our study (Figure 3A). Each relative was tested for
MLH1 methylation by CpG pyrosequencing and genotyped at
multiple polymorphic markers across a 4.3 Mb region encom-
passing the MLH1 locus. Strikingly, the affected mother (I1),
affected brother (II1), and five currently asymptomatic relatives
(II2, II3, II4, III1, III2) spanning all three generations also had
soma-wide MLH1 methylation. The methylation segregated
faithfully with the variant genetic haplotype (marked by the
c.-27C > A and c.85G > T substitutions) and followed an auto-
somal dominant inheritance pattern (Figure 3A). Furthermore,
allelic methylation and expression studies demonstrated at
a molecular level that the promoter methylation and transcrip-
tional repression were linked to the variant haplotype in each
of these family members (Figures 3 and 4; Figures S3A–S3E).
In contrast, no methylation was detected in relatives who did
not carry this variant haplotype (III3, III4, III5), and they each
demonstrated balanced biallelic expression of MLH1 at the
common c.655A > G SNP (Figure 3; Figures S3F–S3H). The
dominant inheritance of the MLH1 epimutation on the variantCancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc. 201
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Figure 1. Soma-Wide Methylation of the
MLH1 Promoter in the Female Proband
(A) Map of CpG methylation pyrosequencing
assay used to measure MLH1 promoter methyla-
tion levels. Gray rectangle; exon with transcrip-
tion start site according to reference sequence
(GenBank accession NM_000249) indicated by
an arrow. +1; A of ATG start codon. Circles:
CpG dinucleotides with the five sites assayed
numbered and filled in gray. Black bar: region
amplified by outer primers (horizontal arrows).
Hexagon: biotinylated primer. An inner primer was
used for pyrosequencing of the biotinylated
strand.
(B) Representative pyrograms show the level of
MLH1 promoter methylation detected in various
normal somatic tissues. Five CpGs interrogated
are shaded yellow and the percentagemethylation
(in blue box) at each site is calculated as the
C:T ratio of peak heights (representing methyl-
ated:unmethylated cytosine).
(C) Sequence electropherogram from genomic
DNA showing heterozygosity for the c.-27C > A
and c.85G > T variants (top). Beneath, plasmid
inserts containing a cloned amplicon show a wild-
type allele, and a variant haplotype bearing both
c.-27A and c.85T variants in cis.
See also Figure S1.
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genetic defect that predisposes this particular haplotype to
epigenetic modification and silencing.
Somatic Allelic Mosaicism
Epigenetic mosaicism was observed as inter-tissue and inter-
individual differences in the extent of MLH1 promoter methyla-
tion and of transcriptional silencing of the variant haplotype in
family 16 (Figures 3B and 3C). Comparison of overall methylation202 Cancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc.levels from four different somatic tissues
(PBL, buccal mucosa, saliva, and hair
follicles), from each of seven carriers of
the variant haplotype (including three
cancer-affected and four unaffected
family members) failed to show a correla-
tion between the degree of methylation
and any particular tissue source or
disease status. However, in the two
affected siblings with colonic mucosa
available (proband II5 and brother II1),
methylation levels were highest in this
tissue (Figure 3B). The inter-individual
variability in overall methylation levels
were best illustrated by two asymptom-
atic relatives, a 22-year-old female (III2)
who had the highest methylation levels
(range, 27.3%–38.5%) and her 49-year-
old uncle (II3) who had the lowest levels
(range, 18.7%–26.0%). Allelic bisulphite
sequencing revealed a heterogeneous
pattern of hypermethylated, partiallymethylated, and unmethylated copies of the variant MLH1
haplotype among the somatic tissues of the epimutation carriers
(Figures 2 and 4; Figures S3A–S3F). Further illustrating this
epigenetic mosaicism, the comparative level of expression of
the variant haplotype in those tissues ranged from 0%–60% of
the wild-type allele (Figure 3C; Figure S3). Interestingly, the
degree of epigenetic silencing also demonstrated a temporal
difference within the same individual. In two PBL samples
collected from the affected brother (II1) at time intervals 2months
Cancer Cell
Dominant MLH1 Epimutation Linked to 50UTR Variantapart, the levels of transcripts derived from the variant haplotype
differed substantially (3.4% and 26.4% of total MLH1 tran-
scripts), yet the methylation levels were similar in both samples
(26.0% and 27.1%) (Figures 3B,3C and 4; Figure S4). Although
transcripts derived from the variant MLH1 haplotype are
presumably generated from those chromosomes that have
escaped promoter methylation, the discordance between the
methylation and transcription levels in these two PBL samples
suggest that some unmethylated copies may also be silenced.
Thus, histone modifications or other nuclear factors may also
induce transcriptional silencing of the variant haplotype in the
absence of CpG methylation.Erasure of the Epigenetic Aberration in the Male
Germline
Allelic methylation analyses and haplotyping demonstrated that
theMLH1 epimutation was transmitted faithfully with the variant
genetic haplotype from the affected brother (II1) to his son (III1)
(Figure 4; Figure S4). To determine if the epimutation was
conveyed through the germline to the next generation with its
epigenetic modifications intact via ‘‘gametic epigenetic inheri-
tance,’’ motile spermatozoa from the affected brother (II1) were
isolated by the swim-up procedure. Methylation analyses using
various techniques showed the spermatozoa cells were unme-
thylated at the MLH1 promoter (Figures 5A–5C). The negligible
amount of MLH1 methylation detected by the most sensitive of
these assays could be attributed to contamination of the sample
with residual somatically-derived genomic DNA, because this
was matched by traces of methylation of the imprinted SNRPN
control gene (Figure 5A). Furthermore, the levels of expression
from both MLH1 alleles were equivalent in spermatozoa, indi-
cating restoration of transcriptional activity from the naked
variant haplotype to normal levels (Figure 5D). This indicates
that the altered epigenetic state associated with the somati-
cally-affected variant haplotype was completely erased in the
male germline, and that the epigenetic aberration was reestab-
lished once more in the soma of the next generation. Further-
more, this showed the variant haplotype has the capacity for
normal transcriptional activity in the absence of repressive
epigenetic modifications.Transcriptional Activity of the Variant Haplotype
Is Dependent on the Epigenetic Status of the CpG
Island Overlapping MLH1 and EPM2AIP1
The MLH1 and EPM2AIP1 genes share the same bi-directional
CpG island promoter, are transcribed head-to-head from oppo-
site strands (Figure 6A), and are epigenetically coregulated (Goel
et al., 2011; Lin et al., 2007). To determine if the epimutation was
confined to this CpG island, or included flanking genes TRANK1
and LRRFIP2 (Figure S5A), the methylation status and allelic
activity of these two genes was investigated. Neither gene was
methylated in family 16 (Figure S5B). Several carriers of the
variant haplotype were heterozygous for common SNPs within
the 30UTR of TRANK1 and LRRFIP2 (Figure 3A). Using these
SNPs for allelic expression studies, we showed that both genes
were biallelically transcribed in LCLs from these individuals (Fig-
ure S5C), indicating the epimutation was localized to theMLH1-
EPM2AIP1 CpG island.Although the MLH1 reference mRNA begins at nucleotide
c.-198 (Figure 2A), distinct mRNA isoforms, namely 1a and
1b, have been isolated from a colorectal carcinoma cell line
(Lin et al., 2007). To identify the major MLH1 transcripts and
their initiation sites in normal somatic cells, 50RACE was per-
formed on PBL mRNA from a healthy individual. We also
identified two prevalent MLH1 isoforms that utilize alternative
exons 1a or 1b (Figure 6A). Interestingly, the dominant tran-
scription initiation site of the 1a isoform was located at c.-29,
just two bases upstream of the c.-27C > A variant. Because
the 1a transcript encompasses both the c.-27C > A and
c.85G > T variants identified in family 16 (Figure 6A), we per-
formed allelic representation analyses on the MLH1-1a and
1b isoforms individually, as well as on EPM2AIP1, to determine
if somatic transcriptional silencing of the variant haplotype
was confined to the MLH1-1a isoform, or if all transcripts
derived from this CpG island were equally affected. Isoform-
specific amplification was performed between MLH1 exons
1a or 1b and exon 9 to encompass the c.655A > G SNP within
exon 8 in LCLs from members of family 16 who are heterozy-
gous for this SNP (proband II5, II3 and III2). Allele quantification
was then performed at the c.655A > G site. Both MLH1 iso-
forms demonstrated a similar extent of allelic expression imbal-
ance (Figure 6B). Allelic expression analyses of EPM2AIP1
in family members who were informative for an expressible
30UTR SNP also revealed a significant allelic expression
imbalance in carriers of the variant haplotype (II5, III2), whereas
balanced EPM2AIP1 expression was observed in a noncarrier
(III3) (Figure 6C). The equivalent reduction in allelic expression
observed for each of the three major transcripts, irrespective
of the precise location of their initiation sites, suggests the
transcriptional activity of the variant haplotype correlates
with the epigenetic state of the shared EPM2AIP1-MLH1 CpG
island.
To further investigate the relationship between epigenetic
modifications and expression of the variant haplotype in
somatic cells, LCLs from family 16 were cultured with a combi-
nation of the demethylating agent 5-aza-20-deoxycytidine (Aza)
and the histone deacetylase inhibitor trichostatin A (TSA). A
significant upregulation of the variant MLH1 haplotype was
observed in the LCLs from carriers following combinatorial
drug treatment, concomitant with a reduction in CpG methyla-
tion levels (Figure 6D) and a partial reversal of histone modi-
fications (Figure S5D). In contrast, no change in the allelic
expression ratio was detected at the c.655A > G SNP in another
family member (III3) who was unmethylated at MLH1 and did
not inherit the variant haplotype (Figure 6D). Similarly, a partial
upregulation of the coaffected EMP2AIP1 allele was observed
in LCLs from carriers of the variant haplotype following treat-
ment with AZA and TSA (Figure 6C). These findings confirm
that the transcriptional activity of the variant haplotype is indeed
epigenetically regulated. This suggests that a fundamental
genetic defect located on the variant haplotype in family 16
induces epigenetic remodeling in somatic cells, which in turn
governs the transcriptional activity of the MLH1-EPM2AIP1
locus. However, this does not rule out the involvement of
additional nuclear interactions that may also mediate tran-
scriptional suppression of unmethylated copies of the variant
haplotype.Cancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc. 203
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Figure 2. Soma-Wide Epigenetic Repression of a Single Allele of MLH1 in the Proband
(A) Map of MLH1 assays used to assess allelic methylation status (black bars) across the c.-27C > A and c.85G > T sites, allele quantification (AQ) of cDNA or
genomic DNA templates (blue bars) at c.85G > T, and AS-ChIP (allele-specific real-time PCR following chromatin immunoprecipitation) to profile histone
modifications at the c.-27C > A site (green). Exons in gray show 50UTR (narrow box) and coding sequence (wide boxes), with transcription initiation site indicated
by a gray arrow. Lollipops; CpG sites, with those analyzed for methylation by clonal bisulphite sequencing filled in gray. Horizontal arrows show primer positions.
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Figure 3. Pedigree of Family 16 Showing Constitutional MLH1 Methylation Segregates with the Variant Genetic Haplotype
(A) Pedigree. Age of cancer diagnosis (black font) and current age of asymptomatic individuals (gray font) is shown. Circles, female; squares, male; filled, affected
methylation carrier; vertical line at center, asymptomatic methylation carrier. Chromosome 3p haplotypes, generated by compiling the genotypes from multiple
SNP andmicrosatellite markers located within or flankingMLH1, are represented as vertical lines and numbered according to the key beneath. Soma-wideMLH1
methylation (Me) segregated faithfully with the variant haplotype, V (in red), marked by the c.-27A and c.85T variants. Other unmethylated genetic alleles are
shown in gray.
(B) Levels of MLH1 methylation as measured in duplicate by CpG pyrosequencing in somatic tissues of family members.
(C) Relative levels of allelic expression ofMLH1 in somatic tissues. Allelic expression ratios (AER) obtained at two expressibleMLH1 SNPs in informative family
members by AQ pyrosequencing of cDNA normalized to genomic DNA from the same tissue. AER of 1.0 indicates equal levels of expression from both alleles.
AER < < 1.0 indicates reduced expression from the variant haplotype.
See also Figure S3.
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Dominant MLH1 Epimutation Linked to 50UTR VariantThe c.-27C > A or c.85G > T Variants Are Implicated
as the Causative Genetic Defect
To search for a germline structural sequence alteration of the
variant haplotype in family 16, the Affymetrix Genome-wide
Human SNP 6.0 array was employed for genotyping and
copy number variant (CNV) analyses of five family members
from all three generations (I1, II2, II4, II5, III2). Three algorithms
(QuantiSNP, PennCNV, COKGEN) were used for CNV estimation
against a reference baseline generated from 300 healthy Cauca-For AQ pyrosequencing, the biotinylated sense strand is indicated by a hexagon
primers ending in C or A were used with a common reverse primer to specificall
(B) Allelic methylation patterns in normal somatic tissues. Clonal bisulphite seque
the (right) T allele at c.85G > T. Each horizontal line represents a single DNA stra
(C) Allele-specific histone modifications in LCLs by AS-ChIP with antibodies targ
provide controls for transcriptionally active and repressed genes, respectively. Me
standard deviation (SD) is shown.
(D) Allelic imbalance inMLH1 expression. Representative pyrograms showing AQ
C-G and A-T alleles in the yellow shaded areas are provided above in blue. Variab
somatic tissues (indicated by downward arrows).
(E) Loss of heterozygosity (LOH) of the wild-type c.85G allele in colorectal tumor
See also Figure S2.sian controls from the Wellcome Trust Case Control Consortium
(Colella et al., 2007). No evidence for any CNV within 30Mb of
MLH1 was found in family 16 (data not shown). Furthermore,
the finding that neighboring genes TRANK1 and LRRFIP2
were structurally and functionally intact argues against a cryptic
genetic defect within either gene that could influence the
epigenetic state of the intervening MLH1-EPM2AIP1 locus.
This suggests the cis-genetic cause of the epimutation is located
within the MLH1-EPM2AIP1 promoter, prompting further. Blue arrow shows internal pyrosequencing primer. For AS-ChIP, two forward
y amplify the c.-27C or c.-27A alleles, respectively.
ncing shows methylation specifically affects the (left) A allele at c.-27C > A and
nd and circles individual CpG sites.
eting specific histone tail moieties at the c.-27C > A site. GAPDH and MyoD
an relative enrichment of gene or allele-specific DNA performed in triplicate ±1
at the c.85G > T site on the complementary strand. Relative peak heights of the
le transcriptional repression of the T allele was detected in cDNAs from normal
DNA is detected compared to normal tissue by AQ pyrosequencing.
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Figure 4. Dominant Transmission of Somatic Epigenetic Silencing ofMLH1 Linked to the Variant Haplotype from the Affected Brother II1 to
his Son III1
(A) AllelicMLH1methylation patterns in somatic tissues from the affected brother II1 and his son III1 by clonal bisulphite sequencing, show promoter methylation
specifically affects the T allele at the c.85G > T SNP in father and son. One representative unmethylated G allele is shown, with the number of replicates of the
same pattern given on the left.
(B) Allelic imbalance in MLH1 expression. Illustrative examples of pyrograms from AQ pyrosequencing at the c.85G > T site on the complementary strand
in genomic DNA and cDNA templates are shown. PBL1 and 2 refer to two separate PBL samples collected from II1 2 months apart. cDNA synthesis and
pyrosequencing were performed in the same batch, hence the difference in allelic expression imbalance observed between these two samples cannot be
attributed to technical vagary.
See also Figure S4.
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Dominant MLH1 Epimutation Linked to 50UTR Variantinvestigation of the germline c.-27C > A and c.85G > T variants.
Neither variant was found in our screen of 303 healthy controls.
The c.-27C > A Variant Alone Diminishes Transcriptional
Activity in Functional Assays
Luciferase reporter assays were performed to determine if the
variant haplotype comprising the c.-27C > A and c.85G > T vari-
ants in tandem reduce transcriptional activity in somatic cells
using constructs containing the wild-type or naked variant
haplotype inserted into the promoterless pGL3-Basic luciferase
reporter vector. A 2.5-fold reduction in normalized luciferase
activity was observed from the variant haplotype compared to
the wild-type allele in transiently transfected HEK293 cells (Fig-
ure 7A). To determine if either the c.-27C > A or c.85G > T substi-
tution in isolation downregulates transcriptional activity, or if the
two variants have an additive effect when located in cis, the
two variants were isolated in separate constructs and assayed
individually. The isolated c.-27C > A variant diminished pro-206 Cancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc.moter activity to a similar extent as the combined variant haplo-
type, whereas the c.85G > T variant produced transcriptional
output equivalent to the wild-type sequence (Figure 7A). Addi-
tional promoter reporter assays were performed whereby the
constructs were stably integrated into the genome of undifferen-
tiated NCCIT embryonal carcinoma cells. NCCIT transfectants
containing the combined variant haplotype and the c.-27C > A
substitution alone showed over 8-fold reduction in luciferase
output compared to the wild-type and c.85G > T sequences (Fig-
ure 7A). This substantial decrease in transcriptional activity
occurred independently of overt epigenetic change, because
no differential methylation or histone modification was observed
between the four transgenicMLH1 constructs (data not shown).
To confirm the c.-27C > A variant solely downregulatesMLH1
promoter activity in the context of the full MLH1 promoter
sequence, additional assays were performed using constructs
containing the entire promoter and 50UTR. A transcriptional
reduction of nearly 3-fold in NCCIT cells (Figure 7A) and
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Figure 5. Erasure of MLH1 Epigenetic Aberration from the Variant Haplotype in the Spermatozoa of Affected Brother II1
(A) Histogram showing levels of hypermethylatedMLH1 and SNRPN alleles in somatic tissues andmotile spermatozoa from II1, asmeasured by quantitative real-
timemethylation-specific PCR. Themean percentage ofmethylation reference (PMR) from reactions performed in triplicate is plotted ± SD. The imprinted SNRPN
is methylated specifically on the maternal allele in somatic cells and detected at 50%, but is unmethylated in spermatozoa due to gametic epigenetic
reprogramming. SNRPN methylation thus serves as a control for contamination of spermatozoa with somatically-derived DNA. Inset, expanded scale showing
negligible levels of MLH1 methylation in spermatozoa are matched by SNRPN, attributable to marginal somatic contamination of the sample.
(B) Clonal bisulphite sequencing of spermatozoa at the c.85G > T site shows erasure of methylation from each T allele.
(C) CpG pyrosequencing confirms erasure of methylation from theMLH1 promoter. Themeanmethylation score across five CpG sites interrogated is given above
the pyrogram.
(D) AQ pyrosequencing at the c.85G > T site shows an equal level of expression from both MLH1 alleles in spermatozoa cDNAs.
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Dominant MLH1 Epimutation Linked to 50UTR Variant1.5-fold in HEK293 cells (Figure 7B) was observed for the c.-27C
> A variant compared to the wild-type. These functional assays
provide supportive evidence that the c.-27C > A substitution
singularly predisposes the variant haplotype in family 16 to tran-
scriptional repression, whereas c.85G > T likely represents a rare
SNP with no detrimental effect on gene function, but which
merely lies in linkage disequilibrium with the true pathogenic
change.
Investigation of Heat-Shock Factor as a Nuclear
Intermediary in Transcriptional Silencing
of the c.-27C > A Variant
An in silico search of databases containing known transcription
factor binding motifs predicted the c.-27C > A variant created
an inverted dyad repeat (AGAAGTTTCC) of the consensus
nGAAn logo for the heat-shock transcription factor (HSF) family
(Figure S6A). To investigate whether HSFs are recruited to the
c.-27C > A variant and cause transcriptional downregulation,
various functional analyses were performed. Electrophoreticmobility shift assays (EMSAs) conducted with nuclear extracts
from NCCIT and heat-stressed HEK293 cells showed HSF2
bound with clear preference to the c.-27C > A variant in vitro
(Figure S6B), whereas HSF1 bound both alleles in HEK293
extracts (Figure S6C). However, no evidence was found to
support a role for HSF in mediating transcriptional silencing of
the c.-27C > A variant allele in luciferase reporter assays con-
ducted in HSF-activated host cells (Figure S6D), or in LCLs
from family 16 that were demethylated then subjected to
heat-stress (Figures S6E–S6F). Because HSFs form trimers on
activation by stress stimuli and bind heat-shock elements that
typically contain a triad of the pentanucleotide logo (Sakurai
and Enoki, 2010), it is possible that the dyad motif created by
the c.-27C > A variant fails to confer sufficient binding affinity
for activated forms of HSF. Interestingly, however, the EMSAs
also showed specific binding of other nucleoproteins unrelated
toHSF to thewild-type sequence in the extracts of both cell types
(Figures S6B–S6C), suggesting the c.-27C > A variant may result
in a loss of interaction with as yet undefined nuclear factors.Cancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc. 207
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Figure 6. Transcriptional Regulation of the Variant Haplotype in Somatic Cells Is Dependent on the Epigenetic Status of the Bidirectional
EPM2AIP1-MLH1 Promoter
(A) Schematic of the CpG island encompassing the transcription initiation sites of EPM2AIP1 and twoMLH1 isoforms, 1a and 1b, as identified by 50RACE in PBL.
Nucleotide numbering is with reference to the translation start site (+1) withinMLH1 exon 1a. Gray rectangles show exons, transcription start sites and orientation
are indicated by arrows. Lollipops, CpG sites. Relative positions of the single nucleotide variants identified within exon 1a in family 16 are shown. TheMLH1-1a
isoform is transcribed from c.-29, the 1b isoform has two transcription start sites 20 bp apart. Exons 1a and 1b represent alternative first exons and splice directly
onto exon 2. The EPM2AIP1 transcription start site is according to GenBank accession NM_014805.
(B)Concomitant allelic silencingof bothMLH1-1a and1b isoforms in carriers of thevariant haplotype.Pyrograms fromAQpyrosequencingat thec.655A>GSNPsite
(shaded yellow) withinMLH1 exon 8 in LCLs from heterozygous carriers of the variant haplotype show a similar reduction of the G allele in both isoforms 1a and 1b.
(C) Representative sequence electropherograms across the A > C SNP (rs9311149) of EPM2AIP is shown for informative individuals; proband II5 and
III2 (carriers of the variant haplotype) and III3 (noncarrier). Loss or significant reduction of the A allele is shown in cDNAs from II5 and III2, indicating EPM2AIP1 is
subject to concomitant transcriptional silencing with MLH1 in family members methylated at the paired locus. Allelic silencing is partially reprieved in LCLs
treated with 5-aza-20-deoxycytidine (Aza) and trichostatin A (TSA). In noncarrier III3, both EPM2AIP1 alleles are represented at similar levels in all cDNAs.
(D) Partial upregulation of the c.85G > T allele concomitant with reduced MLH1 promoter methylation in LCLs treated with Aza and TSA. Above, histogram
showing the mean (±SD) level of expression of the variant c.85T:G allele or c.655G:A in all carriers of the variant haplotype, and noncarrier III3 (*), by AQ
pyrosequencing in treatments performed in triplicate. Below, level ofMLH1 promoter methylation in the same cell treatmentsmeasured by CpG pyrosequencing.
See also Figure S5.
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Figure 7. The variant Haplotype and c.-27C > A Substitution Alone Significantly Reduce MLH1 Promoter Activity in Luciferase Reporter
Assays
(A) Left:mapofMLH1 fragments insertedupstreamof theFirefly luciferase reporter (Luc) inpGL3-Basic.A set of fourMLH1constructs (c.-299 toc.116+80)containing
either the wild-type sequence, variant haplotype (c.-27A and c.85T in cis), c.-27A variant alone, or c.85T alone were created to address the functional relevance
of the two variants together and separately. A second pair of MLH1 constructs (c.-513 to 1) containing the wild-type or c.-27A tested the functional relevance
of the c.-27C > A variant in the context of the fullMLH1 promoter. Variants are marked with an x. Right: Firefly luciferase activity normalized to Renilla luciferase in
HEK293cellscotransfectedwith theRenilla-expressingpRL-TKvector. ForNCCITstable transfectants, luciferaseactivitywasnormalized tocell number.Histograms
show the mean (±SD) normalized luciferase output from transfections performed in triplicate, expressed as a percentage of the pGL3-Control vector.
(B) A further set of constructs containing the core MLH1 promoter with the wild-type c.-27C site mutated to all three other nucleotides was used to test the
functional importance of this nucleotide site. Histogram shows the mean (±SD) relative Firefly luciferase normalized to Renilla luciferase from stable transfections
performed in triplicate, expressed as a percentage of the normalized pGL3-Control vector.
See also Figure S6.
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Dominant MLH1 Epimutation Linked to 50UTR VariantRetention of the Cytosine at Position c.-27 Is Crucial
for Optimal MLH1 Transcription
To determine whether loss of the wild-type cytosine at
nucleotide c.-27, or the nature of the substitution in family 16 is
of greater functional significance, luciferase promoter reporter
assays were performed with constructs containing the fullMLH1
promoter in which the c.-27C was substituted for each of the
other nucleotides. The c.-27C > G and c.-27C > T substitutions
diminished promoter activity to a similar extent as the c.-27C > A(Figure 7B). This suggests that retention of a cytosine at the c.-27
position is required for optimal MLH1 transcriptional perfor-
mance in somatic cells.
DISCUSSION
We show Mendelian inheritance of a constitutionalMLH1 epimu-
tation in a cancer-affected family and demonstrate that the
epimutation is likely to be induced by a c.-27C > A singleCancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc. 209
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Dominant MLH1 Epimutation Linked to 50UTR Variantnucleotide variant within the 50UTR, located just two bases from
the dominant transcription start site. Because the dominant
inheritance pattern of the epimutation implicates a causative cis-
acting genetic defect, we investigated the possibility of large
structural alterations across chromosome 3p, as well as point
mutations within the MLH1 CpG island. We found only germline
c.-27C > A and c.85G > T substitutions within exon 1. Neither
changewas found inhealthy controls.However, this variant haplo-
type has previously been reported to segregate with colorectal
cancer in another family, although epigenetic and expression
studies were not undertaken (Raevaara et al., 2005). The conser-
vative p.A29S amino acid change encoded by the c.85G > T
variant has been shown to function normally in terms of mismatch
repair efficiency, subcellular localization, protein stability and het-
erodimerization, arguing against a role for this variant in altered
protein activity (Raevaara et al., 2005; Takahashi et al., 2007).
Our finding that the epigenetic aberration was localized to the
CpG island promoter shared by MLH1 and EPM2AIP1, and did
not involve neighboring genes, suggested a proximate cis-
genetic cause, further implicating a pathogenic role for one or
both of the single nucleotide variants. Analysis of the variants
separately and together in luciferase promoter reporter assays
led us to conclude that the c.-27C > A variant was the sole cause
of transcriptional repression. We also showed that mutagenesis
of the c.-27C site reduced transcriptional activity, irrespective of
the nature of the nucleotide substitution. This indicates that
the wild-type cytosine needs to be retained at this site for effi-
cient transcription in somatic cells. This nucleotide is located
two bases from the major transcription initiation site of the
MLH1-1a isoform, thus may reside within an important, but as
yet undefined regulatory element. These findings, together
with the preferential binding of undefined nucleoproteins to
the c.-27C allele in vitro, suggest that in somatic cells the
c.-27C > A variant may result in loss of binding of a nuclear factor
necessary for maximal transcription and/or protection from
chromatin modification. The link between loss of MLH1 regula-
tory elements and induction of epigenetic change is supported
by the previous finding of a germline cis-deletion encompassing
c.-68 to intron 2 in an individual with Lynch syndrome who also
displayed constitutional MLH1 methylation (Gylling et al., 2009).
Autosomal dominant sequence-dependent epimutations have
also been described in diseases caused by genes other than
MLH1. In a familial case of a-thalassemia, an interstitial deletion
downstream of HBA2 caused an epimutation of this gene
(Tufarelli et al., 2003).MSH2 epimutations are caused by a similar
mechanism (Ligtenberg et al., 2009). These examples pertain to
epimutations caused by large structural alterations in the vicinity
of the affected gene. To our knowledge the only other instance of
a single nucleotide variant inducing a constitutional epimutation
has been in familial chronic lymphocytic leukemia. In this
study, heritable DAPK1 methylation was associated with a
single nucleotide variant within a regulatory element over 6 kb
upstream, which recruited the HOXB7 repressor (Raval et al.,
2007). In neoplasia, the correlation between particular genotypes
at germline promoter SNPs and the presence of promoter meth-
ylation also suggest an interplay between sequence variation
within functional elements and the epigenetic apparatus, as
exemplified by VHL (Banks et al., 2006), MGMT (Hawkins et al.,
2009; Ogino et al., 2007), and GSTP1 (Rønneberg et al., 2008).210 Cancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc.Our observations regarding the allelic patterns ofMLH1meth-
ylation and expression in a wide range of tissues from members
of family 16 allows us to speculate on the mechanism by which
the epimutation is established on the variant haplotype and
transmitted through the germline (Figure 8). The erasure of meth-
ylation from the variant haplotype and restoration of normal
transcriptional activity in the spermatozoa of the cancer-affected
male first indicates complete but transient reversion of the epige-
netic error in the germline. The coincidence of allelic reactivation
with erasure of the repressive epigenetic components indicates
the variant haplotype is capable of normal transcription in
its epigenetically naked state. Therefore the underlying genetic
defect does not directly abrogate transcription per se. The rein-
statement of the epimutation on the variant haplotype in somatic
cells of successive generations indicates somatic resetting of the
epigenetic error with each new generation. However, significant
epigenetic heterogeneity was observed throughout the soma of
family members, suggesting the underlying genetic defect
confers a propensity for the accrual of repressive chromatin
modifications in a somatic context, which in turn stabilize tran-
scriptional silencing of the variant haplotype. It appears the
variant haplotype may exist in three different methylation and
transcriptional states in somatic tissues (labeled Type I, II, and
III on Figure 8). Some variant alleles were methylated and tran-
scriptionally silent, some were unmethylated and active, yet
others appeared to be unmethylated and transcriptionally silent.
The latter finding, taken together with the observations in
promoter reporter assays, suggests the involvement of an inter-
mediary nuclear factor influencing transcriptional regulation of
the variant allele in somatic but not germ cells. This somatic
factor may take the form of a transcriptional repressor, epige-
netic modifier or noncoding RNA, which is specifically recruited
by the variant haplotype and induces secondary epigenetic
modification. An alternative mechanism would be the loss of
binding of a chromatin insulator that would normally mask the
MLH1 promoter from epigenetic modification (Figure 8).
Irrespective of the precise mechanism of epigenetic suppres-
sion, it isprobable that thevariantgenetichaplotypeofMLH1 iden-
tified in family 16 confers cancer susceptibility. Our study should
prompt a reevaluation of the pathogenicity of several germline
variants identified within theMLH1 50UTR and promoter in Lynch
syndrome cases, such as at the neighboring c.-28 nucleotide
(Isidro et al., 2003; Mu¨ller-Koch et al., 2001).These variants may
similarly confer cancer-susceptibility by mediating allelic epige-
netic inactivation. Finally our study lends weight to recent reports
correlating allele-specificmethylation in a small number of nonim-
printed genes with particular SNP genotypes (Kerkel et al., 2008;
Zhang et al., 2009). Although evidence for genotype-epigenotype
interactions is currently limited, our study suggests that germline
single nucleotide variants in gene regulatory elements may play
a generalized role in inducing epigenetic silencing of tumor
suppressor and other disease-associated genes.
EXPERIMENTAL PROCEDURES
Subjects
This study was approved by the Human Research Ethics Committee of
St. Vincent’s Hospital Sydney and subjects provided written consent. Clinical
specimens were handled as described in Supplemental Experimental
Procedures.
Figure 8. Model of the Potential Mechanism byWhich the VariantMLH1 Haplotype Induces a Soma-Wide Epimutation and Its Mode of Inter-
generational Transmission
Wild-type (blue) and variant (purple) MLH1 alleles and their color-coded mRNA transcripts are shown within somatic or germ cells. The c.-27C > A variant is
indicated by a white x and promoter methylation and repressive histone marks are a pink rectangle. Transcriptional activity is indicated by black arrows. In green,
transcription activators (A) are represented by a circle, transcription repressors or chromatin modifiers (R) by a triangle, and chromatin insulators (I) by a square.
Top right: the variantMLH1 haplotype is shown in three different epigenetic states in adult somatic cells. In some cells (type I) the variant haplotype is methylated
and transcriptionally silent, in other cells (type II) the haplotype is unmethylated and accessible to transcription activators. For type III, it is inferred that the allele is
unmethylated but transcriptionally repressed by a putative intermediary nuclear factor. This may take the form of a repressive complex that is recruited to the
allele and mediates chromatin modulation, or loss of a protective insulator that normally prevents chromatin modification.
Bottom right: inmature spermatozoa the variant haplotypewas completely unmethylated and this coincidedwith restoration of transcription, indicating erasure of
the epimutation in gametes. This shows the variant haplotype is inherently capable of normal transcriptional activity in its naked form. Left: the epimutation is
reestablished with each new generation. This is predicted to occur contemporaneously with de novo methylation of other genomic loci in somatic cells of the
gastrulating embryo during germ cell lineage commitment. The variant haplotype confers a susceptibility to aberrant de novo methylation through altered
interaction with an intermediary nuclear factor(s). Mosaicism may be attributable to competition for occupancy between transcription activators and chromatin
modifiers. The three epigenetic states established on the variant haplotype are maintained through mitosis into adulthood, with the onset of methylation
permanently stabilizing epigenetic silencing of the affected allele. Erasure of the epimutation from the variant haplotype most likely occurs in the primordial germ
cells (PGC) as they migrate through the genital ridge of the developing embryo to become gamete precursors. This process most likely occurs by active
demethylation, coinciding with epigenetic reprogramming of imprinted genes. Picture of spermatozoan kindly provided by BIODIDAC.
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Genomic DNA (1 mg) was treated with sodium bisulphite using the EZ Methyl-
ation Gold Kit (Zymo Research) and 100 ng used for PCR. MLH1 methylation
levels were determined by CpG pyrosequencing, as previously described
(Goel et al., 2011). For allelic methylation analyses, PCR was performed with
primers flanking the c.-27C > A or the c.85G > T variants that were unbiased
with respect to methylation status (Supplemental Experimental Procedures).
Amplicons were cloned in the pGEMTEasy vector (Promega), plasmids iso-
lated from single bacterial colonies, and clonal bisulphite sequencing of inserts
was performed using vector primers. Quantitative real-time methylation
specific PCR was performed as previously described (Hitchins et al., 2007;
Kwok et al., 2010).
Allelic Representation Analyses
Allelic expression and LOH analyses were performed by AQ pyrosequencing
at the c.85G > T site from the complementary (C > A) strand. First-strand
cDNAs and genomic DNA templates were PCR-amplified using the same
biotin-labeled forward primer, but different reverse primers; a primer spanning
the junction of exons 1 and 2 for cDNAs and an intronic primer for genomicDNA. Pyrosequencing of the denatured biotinylated strand from both
cDNA and DNA templates was performed in the antisense direction using
the same pyrosequencing primer and nucleotide dispensation order
GACATGCGCTG to interrogate sequence A/CTGGCCGCTGG. Primer
sequences are given in Supplemental Experimental Procedures. The Pyro-
Mark AQ software was used to determine the relative percentage of each allele
based on peak height. To normalize for any systematic bias in the AQ assay,
allelic expression ratios (AER) were normalized to genomic DNA, calculated
as (cDNA%A/cDNA%C)/(DNA%A/DNA%C). LOH in tumor DNA (T) was sought
compared to normal DNA (N) using the LOH index calculated as (T%A/T%C)/
(N%A/N%C) and defined as an LOH index <0.6 or >1.7. AQ pyrosequencing
at the c.655A > G SNP was performed as previously described (Kwok et al.,
2010), with AER and LOH values calculated as the ratio of G:A. Allelic
expression analysis of EPM2AIP1 was performed as previously described
(Goel et al., 2011).
Allele-Specific Chromatin Immunoprecipitation
LCLs (6 3 106) were fixed in 0.1% formaldehyde and subjected to ChIP using
the Millipore Magna ChIP A Chromatin Immunoprecipitation Kit (Millipore).Cancer Cell 20, 200–213, August 16, 2011 ª2011 Elsevier Inc. 211
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Dominant MLH1 Epimutation Linked to 50UTR VariantRabbit polyclonal antibodies; anti-H3K9 acetylation, anti-H3K9me3, anti-
H3K27me3, anti-H3K4me3, and IgG control (Millipore) were used. Semiquan-
titative real-time PCR ofMLH1 was performed using two forward primers that
differed only at the final 30 base to specifically amplify the c.-27A or the c.-27C
allele in separate reactions, in combination with the same reverse primer. Rela-
tive enrichment of each histone modification was calculated as 2DCt (input-eluate)
for each locus, with background 2DCt (input-IgG negative control) subtracted.
Treatment with Epigenetic Reversal Drugs
LCLs (2 3 105/ml) were cultured in media containing 8 mM 5-Aza-20-deoxycy-
tidine for 72 hr with daily drug replenishment. Cells were then treated with
medium containing 300 nM trichostatin A for a further 24 hr. Mock-treatments
were performed with drug diluent. Cells were cultured for a further 72 hr
without drug prior to harvesting.
Luciferase Promoter Reporter Assays
Promoter reporter constructs containing MLH1 sequences inserted into the
pGL3-Basic vector (Promega) upstream of the Firefly luciferase reporter
were transfected into HEK293 and NCCIT cells (Supplemental Experimental
Procedures). Briefly, transfections were performed in triplicate in parallel
with the pGL3-Control luciferase reporter under the SV40 promoter, and
empty pGL3-Basic vector. HEK293 cells were cotransfected with pRL-TK
Renilla luciferase reporter to normalize for transfection efficiency. NCCIT
stable transfectants were normalized by cell count and plasmid integration
rates were measured by real-time PCR of host genomic DNA.
ACCESSION NUMBERS
The Affymetrix Genome-wide Human SNP 6.0 array data is deposited in Gene
Expression Omnibus accession number GSE30348.
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